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Abstract
Background: Members of the genus Nocardia are ubiquitous environmental saprophytes capable to cause human
pulmonary, disseminated and cutaneous nocardiosis or bovine mastitis. Innate immunity appears to play an
important role in early defense against Nocardia species. To elucidate the contribution of antimicrobial peptides
(AMPs) in innate defense against Nocardia, the activity of human a-defensins human neutrophil peptides (HNPs) 1-
3, human b-defensin (hBD)-3 and cathelicidin LL-37 as well as bovine b-defensins lingual and tracheal antimicrobial
peptides (LAP, TAP) and bovine neutrophil-derived indolicidin against four important Nocardia species was
investigated.
Results: Whereas N. farcinica ATCC 3318 and N. nova ATCC 33726 were found to be susceptible to all investigated
human and bovine AMPs, N. asteroides ATCC 19247 was killed exclusively by neutrophil-derived human a-defensins
HNP 1-3 and bovine indolicidin. N. brasiliensis ATCC 19296 was found to exhibit complete resistance to investigated
human AMPs and to be susceptible only to bovine indolicidin.
Conclusion: Selected AMPs are capable to contribute to the first line of defense against Nocardia, yet,
susceptibility appears to vary across different Nocardia species. Obtained results of neutrophil-derived AMPs to
possess the broadest antinocardial spectrum are remarkable, since nocardiosis is characterized by a neutrophil-rich
infiltrate in vivo.
Background
Nocardia represent a genus of aerobic actinomycetes and
belong specifically to the family Mycobacteriaceae [1].
Nocardia are aerobic, gram-positive, filamentous,
branching rods and can be found as ubiquitous environ-
mental saprophytes in soil, dust, organic matter and
water. Due to recent advances in phenotypic and molecu-
lar characterization (especially 16S rRNA gene sequen-
cing) the spectrum of Nocardia has expanded, with more
than 30 species described [2]. At least 13 Nocardia spe-
cies have been implicated in human infection with vary-
ing geographic prevalence throughout the world [3].
Human infections usually arise from inhalation or
direct inoculation into skin or soft tissue structures.
Major forms of Nocardia infection are pulmonary
nocardiosis, disseminated and CNS nocardiosis, cuta-
neous/lymphocutaneous nocardiosis and mycetoma.
Nocardiosis may be considered as opportunistic
infection with chronic lung disease (often in association
with long-term corticosteroid treatment), transplanta-
tion, malignancies, diabetes mellitus and alcohol abuse
as most prevalent underlying conditions [4]. Neverthe-
less, a review of more than 1000 cases of Nocardia
infection revealed no identifiable predisposing immuno-
compromising factors in approximately 30% of patients
[5]. Additionally, Nocardia are well-recognized patho-
gens in animals with bovine masititis representing the
most important infection.
The characteristic histopathological feature of nocar-
diosis consisting of an acute pyogenic inflammatory
reaction i.e. a predominant neutrophil-rich infiltrate as
well as results of prior studies point towards an impor-
tant role of innate defense mechanism against Nocardia
species.
Antimicrobial peptides (AMPs) represent evolutiona-
rily conserved multifunctional molecules of innate
immunity. In mammals, AMPs like human b-defensins
(hBD) 1-3 and bovine lingual or tracheal antimicrobial
peptide (LAP, TAP) are expressed by cells within the
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any medium, provided the original work is properly cited.epithelial lining or are delivered to sites of infection by
circulating leukocytes [6-8]. Examples of the latter
group of AMPs include human neutrophil peptides
(HNPs) 1-3, bovine indolicidin or human cathelicidin
LL-37 [9-11]. AMPs are produced constitutively or are
induced upon infection or inflammation and exert activ-
ity against a broad spectrum of microorganisms includ-
ing gram-positive and gram-negative bacteria, enveloped
viruses, protozoa and fungi [12]. Apart from a direct
microbicidal effect, AMPs exhibit a variety of additional
functions by promoting chemotaxis and phagocytosis,
stimulating angiogenesis and wound healing or neutra-
lizing LPS effects [13].
There is increasing evidence that AMPs take part in
innate defense against Nocardia-related bacteria such as
Mycobacterium tuberculosis [14] or Actinomyces israelii
and naeslundii [15]. The aim of the current study was
to elucidate the contribution of AMPs in innate immu-
nity against different Nocardia species. We therefore
investigated the activity of several important epithelial-
and neutrophil-derived human and bovine AMPs against
the four nocardial species N. farcinica, N. nova, N. aster-
oides and N. brasiliensis,a l lo fw h i c h r e p r e s e n tm a j o r
human and bovine pathogens.
Results and Discussion
Levofloxacin was used as killing control to compare
antinocardial potency of tested AMPs and showed dose-
dependent activity against all four nocardial strains. The
peptide DPY without antimicrobial activity served as
negative control and exhibited no activity against all
tested Nocardia strains (data not shown).
Activity of human AMPs against Nocardia species
All tested human AMPs exhibited activity against N. far-
cinica ATCC 3318 (Figure 1A) and N. nova ATCC 33726
(Figure 1B). Human b-defensin hBD-3 revealed strongest
activity with LD90 of 16 μg/ml against both strains.
Figure 1 Activity of human AMPs HNP 1-3, hBD-3, LL-37 and levofloxacin (killing control) against A N. farcinca ATCC 3318 (p < 0.05 for
all tested substances), B N. nova ATCC 33726 (p < 0.05 for all tested substances), C N. asteroides ATCC 19247 (levofloxacin p < 0.05, HNP1-3 p =
0.11) and D N. brasiliensis ATCC 19296 (levofloxacin p < 0.05) was investigated using a colony forming unit (CFU) assay. Data are means (percent
CFU reduction) of at least four independent sets of experiments with each peptide and each Nocardia species.
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respectively. Accordingly, we found human a-defensins
HNP 1-3 to be active, although higher concentrations
were needed with LD90 >32 μg/ml against N. farcinica
and LD90 of 64 μg/ml against N. nova (Table 1). Notably,
hBD-3 and LL-37 were found to be more potent against
N. nova than levofloxacin in equivalent concentrations.
To address additive or synergistic effects of AMPs, we
performed a model assay using N. farcinica and a combi-
nation of LL-37 and HNP 1-3 (Figure 2). Since the com-
bination of the two AMPs exhibited nocardial killing
comparable to each peptide alone at twofold higher con-
centrations, we found additive activity of the two AMPs.
In contrast to results with N. farcinica and N. nova,
hBD-3 and LL-37 did not show antinocardial activity
against N. asteroides ATCC 19247 (Figure 1C). Only
human a-defensins HNP 1-3 were found to be active
against N. asteroides with LD90 of 32 μg/ml.
N. brasiliensis ATCC 19296 proved to be resistant to
all human AMPs tested since neither HNP 1-3 nor
hBD-3 or LL-37 exhibited killing activity in concentra-
tions up to 64 μg/ml (Figure 1D). Remarkably, stronger
growth of N. brasiliensis was observed with all three
AMPs investigated. Enhanced growth was not found
after incubation with equivalent concentrations of DPY
(data not shown). To investigate whether proteolytic
degradation of AMPs by N. brasiliensis-derived pro-
teases might play a role, we added a protease inhibitor
mix during incubation in CFU assays. Protease inhibi-
tors were not able to alter the observed AMP resistance
of N. brasiliensis, yet enhanced growth of N. brasiliensis
after co-incubation with protease inhibitors could be
observed again(data not shown).
Activity of bovine AMPs against Nocardia species
CFU-assays revealed activity of all tested bovine AMPs
against N. farcinica ATCC 3318 (Figure 3A). Neutro-
phil-derived indolicidin and bovine b-defensin LAP
showed potent killing with LD90 of 16 μg/ml respec-
tively. Bovine TAP was also active, LD90 proved to be
32 μg/ml. All bovine AMPs revealed at least comparable
or greater activity at 32 μg/ml against N. farcinica than
levofloxacin. Accordingly, bovine indolicidin exhibited
killing activity against N. nova (LD90 8 μg/ml) and N.
asteroides (LD90 64 μg/ml) (Table 1).
In contrast to human AMPs, bovine indolicidin exhib-
ited activity against N. brasiliensis ATCC 19296, thus,
representing the sole AMP capable to kill N. brasiliensis
(Figure 3B). LD90 of indolicidin was 64 μg/ml. Accord-
ing to results of hBD-3, N. brasiliensis proved to be
resistant to bovine b-defensins LAP and TAP. Again,
pronounced growth was observed after incubation with
both AMPs (data not shown).
AMPs are effector molecules of innate immunity and
provide a first line of defense against invading patho-
gens. Our investigations reveal a differential activity of
epithelial- and neutrophil-derived AMPs against four
members of the genus Nocardia.W h e r e a sN. farcinica
and N. nova were found to be susceptible to all investi-
gated human and bovine AMPs, N. asteroides was killed
exclusively by human a-defensins HNP 1-3 and bovine
indolicidin.
Host-pathogen interactions in Nocardia species have
been extensively studied (for review see Beaman et al.)
[5]. Severity and manifestations of nocardiosis are influ-
enced by the portal of entry, tissue tropism, inoculum
dose and virulence characteristics of the infecting
Nocardia strain and, conversely, the efficacy/virtue of
the mounted host immune response. Innate defense
mechanisms, specifically killing and elimination by neu-
trophils and macrophages appear to be of particular
importance for the outcome of nocardiosis. Although
insufficient to resolve infection, the early phagocyte
attack is considered to retard infection until lympho-
cyte-mediated cytotoxicity and activated macrophages
accomplish a definite response [16-18].
Table 1 Susceptibility of different Nocardia species against innate defense AMPs
LD90(μg/ml)
(killing/CFU reduction in percent ± SD)
Species levoflox HNP 1-3 LL-37 hBD-3 indolicidin LAP TAP
N. farcinica ATCC 3318 8
(92.3 ± 3.8)
>32 32
(96.6 ± 0.6)
16 (92.5 ± 5.3) 16
(96.7 ± 1.7)
16
(92.9 ± 7.1)
32
(94 ± 5.1)
N. nova ATCC 33726 >32 64
(97.2 ± 3.6)
32
(91.4 ± 7.0)
16
(95.2 ± 1.7)
8
(90.5 ± 3.4)
n.d. n.d.
N. asteroides ATCC 19247 8
(92.6 ± 3.8)
32
(90.9 ± 0.6)
>64 >64 64
(99.1 ± 0.6)
n.d. n.d.
N. brasiliensis ATCC 19296 32
(96.6 ± 2.2)
>64 >64 >64 64
(92.9 ± 2.1)
>64 >64
LD90 denotes the lowest peptide concentration leading to a = 90% reduction of CFU after incubation (12 h or 16 h) with AMPs or levofloxacin. Presented data
are LD90 determinations based on means of at least four (levofloxacin, HNP 1-3, LL-37 and hBD-3) or two (indolicidin, LAP and TAP) independent sets of
experiments with each Nocardia species. In brackets are means (percent CFU reduction) ± standard deviation of respective experiments.
SD standard deviation, n.d. not determined
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Page 3 of 8Figure 2 Additive activity of the two AMPs HNP 1-3 and LL-37 in a colony forming unit (CFU) assay against N. farcinica ATCC 3318.A
combination of HNP 1-3 and LL-37 exhibited killing comparable to each peptide alone at twofold higher concentrations (i.e. 78.9% CFU
reduction by 8 μg/ml HNP 1-3 in combination with 8 μg/ml LL-37 compared to 68.5% CFU reduction by 16 μg/ml LL-37 or 45.6% reduction by
16 μg/ml HNP 1-3 alone). Data are results of a single assay.
Figure 3 Activity of bovine AMPs TAP, LAP indolicidin and levofloxacin (killing control) against A N. farcinca ATCC 3318 (p < 0.05 for all
tested substances), B N. brasiliensis ATCC 19296 (indolicidin and levofloxacin p < 0.05) was investigated using a colony forming unit (CFU) assay.
Data are means (percent CFU reduction) of at least two independent sets of experiments with each peptide and each Nocardia species.
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isms of neutrophils, we propose AMPs to contribute to
the early phase of defense against various Nocardia spe-
cies. Interestingly and in favour of our hypothesis, we
found neutrophil-derived AMPs such as human HNP 1-
3 and bovine indolicidin to have broader antinocardial
activity than the investigated epithelial AMP hBD-3
(albeit in equimolar concentrations hBD-3 exhibited
greater CFU reduction/killing of N. farcinica and N.
nova than HNP1-3). Moreover, besides their abundant
presence in neutrophils, AMPs are produced by other
innate defense effector cells. LL-37 and, to a lesser
extent, HNP 1-3 were found in monocytes/macrophages,
NK cells and gδ T cells [19], which are also considered
to take part in antinocardial defense.
Several virulence determinants of Nocardia including
lysozyme resistance and inhibition of phagosome-lyso-
some fusion have been described [20]. Due to prior
investigations, host-pathogen interactions are best chara-
terized in N. asteroides infection. A distinct feature of
virulent strains of N. asteroides is the capability to resist
to oxidative burst-mediated killing by phagocytes due to
catalase [21] and superoxide dismutase production [22].
Here we found HNP 1-3 and indolicidin to represent
nocardicidal effector molecules belonging to the arma-
ment of non-oxidative killing mechanisms of neutro-
phils. In accordance with our observations, Filice et al.
found neutrophil granule-derived cationic proteins (con-
taining HNP 1-3) to inhibit N. asteroides growth and
filament formation [23].
In human neutrophils, a-defensins HNP 1-3 are
stored as active peptides in primary (azurophil) gran-
ules in concentrations of >10 mg/ml [24]. As granule-
contents are minimally diluted after fusion with the
phagocytic vacuole, HNP 1-3 targets ingested patho-
gens in concentrations multitudes higher than those
needed for potent antinocardial killing observed in our
study (LD90 of N. farcinca, N. nova and N. asteroides =
64 μg/ml). In contrast, the human cathelicidin is stored
as inactive precursor hCAP-18 in secondary (specific)
granules and is processed to LL-37 by proteinase 3
after secretion into the extracellular milieu. Like the
human b-defensin hBD-3, LL-37 is additionally pro-
duced upon infection or inflammation by epithelial
cells of the respiratory/gastrointestinal tract or by kera-
tinocytes. Levels of LL-37 e.g. in airway surface fluids
are estimated to be 1-5 μg/ml [25]. Concentrations
of b-defensins are estimated to be in the range of 1-10
μg/ml [13]. Thus, in vivo concentrations of LL-37 and
hBD-3 will most likely be not sufficient to exert direct
nocardial killing. Nevertheless, LL-37 and hBD-3 may
take part in antinocardial defense by additive or syner-
gistic action with other antimicrobial peptides and pro-
teins abundantly present along epithelial barriers. In
favour of this hypothesis, we found additive killing of
N. farcinica i nam o d e la s s a yu s i n gac o m b i n a t i o no f
LL-37 and HNP 1-3. Moreover, owing to a wide range
of biological activities, LL-37 and hBD-3 may further
contribute due to chemotactic effects on neutrophils,
monocytes and T cells [26,27].
We found N. brasiliensis to exhibit complete resis-
tance to all investigated human AMPs and to be suscep-
tible only to bovine indolicidin. N. brasiliensis is the
most frequently reported cause of progressive cutaneous
and lymphocutaneous disease. Furthermore, N. brasi-
liensis often causes infection in otherwise immunocom-
petent hosts. These clinical features are in accordance
with our findings, demonstrating a complete resistance
of N. brasiliensis against human epithelial, i.e. keratino-
cyte-derived and neutrophil-derived AMPs.
N. brasiliensis is known to produce a variety of
proteases [28]. To evaluate a potential resistance due to
proteolytic degradation of AMPs (particularly linear
a-helical LL-37), CFU-assays were conducted in the
presence of protease inhibitors. However, protease inhi-
bitors did not alter AMP-resistance in N. brasiliensis.
One might speculate about species-specific variances in
b a c t e r i a lc e l lw a l lc o n s t i t u e nts yielding to differential
nocardial AMP susceptibility/resistance [29]. Addition-
ally, other mechanisms, i.e. active efflux by multi-drug
transporters or modifications on the bacterial cell
surface may confer AMP resistance.
The current study revealed N. brasiliensis to be sus-
ceptible only to indolicidin, a tryptophan- and proline-
rich 13 amino acid peptide of bovine neutrophils. In
contrast to the predominantly membrane-active human
defensins and cathelicidin LL-37, indolicidin has been
referred to exert intracellular modes of action with inhi-
bition of DNA and protein-synthesis and alteration of
cytoplasmic membrane septum formation [30]. Thus, its
distinct chemical features and alternative mode of action
may contribute to the unique activity of indolicidin
against N. brasiliensis.
Conclusions
Selected AMPs are capable to contribute to the first line
of defense against Nocardia, yet, susceptibility appears
to vary across different Nocardia species. Interestingly,
our finding of neutrophil-derived AMPs to possess a
broad antinocardial spectrum is paralleled by the char-
acteristic feature of a neutrophil-rich infiltrate in histo-
pathological specimens of nocardiosis. Moreover, the
observed resistance of N. brasiliensis is remarkable,
since N. brasiliensis is frequently reported to cause cuta-
neous and lymphocutaneous disease in otherwise immu-
nocompetent hosts. Further studies should address in
more detail the differential activity of AMPs, its causes
and pathophysiologic significance.
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Bacterial strains and culture conditions
Four strains of the genus Nocardia were investigated:
Nocardia farcinica (ATCC 3318), Nocardia nova
(ATCC 33726), Nocardia asteroides (ATCC 19247) and
Nocardia brasiliensis (ATCC 19296). Strains were
grown on Columbia blood agar for at least 72 hours at
37°C. Then 30 ml of Mueller-Hinton-broth (MHB) sup-
plemented with 1% Tween 80 (Serva, Heidelberg, Ger-
many) was inoculated with one loop of bacteria scraped
off the agar plates. MHB was incubated in a shake incu-
bator (220 rpm at 37°C). 10 ml of the culture was trans-
ferred to a 50 ml tube which contained 1 mm glass
beads (BioSpec Products, Bartlesville, USA). After vor-
texing for 10-15 seconds a homogenous suspension
could be gained. A few millilitres of the suspension were
used to inoculate another 50 ml of MHB (also supple-
mented with 1% Tween 80). Cultures were incubated
until mid-logarithmic phase was reached. Incubation
times were different for each Nocardia species (N. farci-
nica 12 h, N. nova 24 h, N. asteroides 16 h, N. brasilien-
sis 72 h).
Innate defense antimicrobial peptides
The activities of major human and bovine AMPs
belonging to different families of AMPs were tested
(summarized in Table 2): human cathelicidin LL-37,
human a-defensins human neutrophil peptides 1-3
(HNP 1-3) and human b-defensin-3 (hBD-3), bovine
indolicidin and bovine b-defensins lingual antimicrobial
peptide (LAP) and tracheal antimicrobial peptide (TAP).
Human cathelicidin LL-37, bovine indolicidin, LAP and
TAP were synthesized using standard Fmoc/tBu chemis-
try on a multiple peptide synthesizer Syro II (MultiSyn-
Tech, Witten, Germany). Oxidation of the reduced LAP
and TAP was achieved by dissolving the prepurified
peptide with 2 M acetic acid and dilution to a peptide
concentration of 0.015 mM in the presence of reduced/
oxidized glutathione (molar ratio of peptide/GSH/GSSG
was 1:100:10) and 2 M guanidine hydrochloride. The
solution was adjusted to pH 8.0 with aqueous NH4OH
a n ds t i r r e ds l o w l ya t4 ° Cf o r3d a y s .T h ef o l d i n g
reaction was monitored by analytical HPLC. The solu-
tion was concentrated using a C18 Sep-Pak cartridge
(Waters, Milford, USA) and lyophilized. Purification of
the oxidized products was achieved first by chromato-
graphy on a C8 column using the system above and
yielding a purity of 90%. Finally, the product was highly
purified on a C18 column using a 60 min gradient
resulting in a purity of 95%. The quality of the product
was confirmed by analytical HPLC, matrix-assisted laser
desorption/ionization time of flight mass spectrometry
(MALDI-MS), and electrospray ionization mass spectro-
metry (ESI-MS), yielding the correct mass of oxidized
products. Human a-defensins HNP 1-3 were isolated
from peripheral neutrophils as previously described [31].
Synthetic hBD-3 was purchased from PeptaNova, Sand-
hausen, Germany.
Levofloxacin (Roussel-Uclaf, Romainville, France) was
used as killing control and dissolved in water. A 30
amino acid peptide named DPY without antimicrobial
activity was used as negative control [32]. DPY was
synthesized using standard F-moc/tBu chemistry and
purified by HPLC according to the protocol used for
HNP 1-3. All peptides were dissolved in 0.01% acetic
acid. Antimicrobial agents were stored at -20°C and
were defreezed and freezed three times at a maximum
to ensure full antimicrobial activity.
Colony forming unit assay
A colony forming unit (CFU) assay was established and
performed to test AMP susceptibility. Mid-logarithmic
growth phase cultures were washed twice in 10 mM
sodium phosphate buffer (ph 7.4). A standard inoculum
of 1 × 10
7CFU/ml in 10 mM sodium phosphate buffer
supplemented with 1% MHB was prepared. 80 μlo ft h e
standard inoculum were incubated with 20 μlo ft h e
respective concentrations of the antimicrobial agents in
the shake incubator at 37°C for 12 h (N. farcinica)t o
16 h (N. nova, N. asteroides and N. brasiliensis). Incuba-
tion was carried out in 2 ml tubes (Eppendorf, Ham-
burg, Germany) which were occluded by LidBacs
(Eppendorf, Hamburg, Germany) to avoid contamina-
tion and provide constant aerobic conditions. After
Table 2 Features of human AMPs used in this study
AMP class/structure origin expression pattern
LL-37 cathelicidin, a-helical peptide human neutrophils, monocytes/macrophages (constitutive); epithelial cells of respiratory, gastrointestinal
and urogenital tract, keratinocytes (inducible)
HNP 1-3 a-defensins, b-sheet peptides human neutrophils (constitutive)
hBD-3 b-defensin, b-sheet peptide human epithelial cells of respiratory and gastrointestinal tract, keratinocytes (inducible)
indolicidin linear, tryptophan- and
proline-rich peptide
bovine neutrophils (constitutive)
LAP b-defensin, b-sheet peptide bovine epithelial cells of respiratory and gastrointestinal tract, mammary gland (inducible)
TAP b-defensin, b-sheet peptide bovine epithelial cells of respiratory tract (inducible)
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ton agar plates and visible colonies were counted after
48-72 hours of incubation at 37°C. Killing was expressed
in percentage of bacteria that were killed by incubation
with respective peptide concentrations compared to
incubation with solvent of the antibacterial substance
(0,01% acetic acid or water). LD90 denotes the lowest
peptide concentration leading to a =90% reduction of
CFU counts. CFU assays were at least performed three
times and final results are displayed as mean value of all
assays. Killing activity (CFU counts after incubation with
solvent vs. CFU counts after incubation with highest
concentration of AMPs or levofloxacin) was analysed by
Student’s t-test. A p-value < 0.05 was considered
significant.
For testing N. brasiliensis, CFU assays were addition-
ally performed by adding a protease inhibitor mix
(Complete Mini, Roche, Mannheim, Germany). 10 μlo f
the protease inhibitor mix were added to the standard
inoculum during the 16 h incubation period. Further
testing was performed as described above.
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